Peptide Science
What happens when scientists target the powerhouses inside a dog's cells?
SS-31 research gives us an intriguing look at mitochondrial health in canines.
Every step. Every heartbeat. Every tail wag. Every cell needs energy.
Mitochondria help make that possible. As animals age, mitochondrial function can change — and that is why scientists are interested in compounds designed to interact with mitochondrial biology.
SS-31, also known as elamipretide, is a short synthetic peptide that concentrates in the inner mitochondrial membrane by binding a lipid called cardiolipin.
It remains an early-stage, emerging compound for cellular energy and aging support. Canine model research is not the same as an approved or validated treatment for aging dogs.
Why mitochondria matter
Mitochondria are where most of the body's usable energy is produced. Tissues with relentless energy demand — heart, kidney, brain, working muscle — depend on them most.
Those are also the tissues that most often set the limit on how good an older dog's days are.
What scientists studied
Research has examined whether stabilising cardiolipin helps preserve the machinery of energy production, and whether that shows up as measurable function in the heart and other high-demand tissues.
Elamipretide has also been through human clinical trials in specific mitochondrial conditions, where results have been mixed and several trials did not meet their primary endpoints.
What happened in the canine research
Canine work sits in research settings — cardiovascular and mitochondrial models — rather than in studies of pet dogs living at home.
The verified studies below report changes in cardiac, skeletal-muscle and mitochondrial measures in small groups of dogs with experimentally induced heart failure. They did not test ordinary aging, lifespan or survival.
Heart function
Cardiac research is the most developed thread. The heart's energy dependence makes it a logical first place to look for any mitochondrial effect.
Mitochondrial function
Measures in this field typically involve respiration, oxidative stress markers and membrane integrity — laboratory readouts, not things an owner can see.
Cellular energy
The hope behind this work is that better cellular energetics support function at the level owners actually notice: willingness to move, stamina on a walk, recovery the next day.
That connection remains a hypothesis in dogs.
Why longevity researchers care
Mitochondrial change is one of the widely recognised features of aging biology. A compound that reaches mitochondria directly is a tool for asking whether that feature can be influenced at all.
What we still need to learn
Whether mitochondrial protection translates into observable function in an aging pet dog.
Which organ system, if any, would show benefit first.
Why human trials have struggled to confirm effects, and what that implies for other species.
Actual studies
- Controlled canine heart-failure modelPubMed PMID 26839394
Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure
Sabbah HN, Gupta RC, Kohli S, et al. Circulation: Heart Failure. 2016;9(2):e002206.
- Study design
- Randomized controlled preclinical study lasting three months.
- Population
- Fourteen dogs with microembolization-induced heart failure: seven treated and seven saline controls.
- Intervention
- Elamipretide compared with saline in an experimentally induced heart-failure model.
- What was measured
- Left-ventricular ejection fraction, NT-proBNP, inflammatory biomarkers, mitochondrial respiration, membrane potential, ATP synthesis and ATP/ADP ratio.
- What the paper reported
- The treated group showed reported improvements in ejection fraction, NT-proBNP and several mitochondrial measures relative to pretreatment or control values.
- Important limitations
- A small, experimentally induced disease model from one research group; it did not study naturally occurring aging, lifespan or survival. The work was supported by the compound's developer, and author financial relationships were disclosed.
- Canine skeletal-muscle mechanistic studyPubMed PMID 30688415
Effects of Elamipretide on Skeletal Muscle in Dogs With Experimentally Induced Heart Failure
Sabbah HN, Gupta RC, Singh-Gupta V, Zhang K. ESC Heart Failure. 2019;6(2):328–335.
- Study design
- Controlled three-month animal study with additional experiments on isolated muscle mitochondria.
- Population
- Seven normal dogs, seven dogs with induced heart failure receiving elamipretide and seven receiving vehicle.
- Intervention
- Elamipretide compared with vehicle; isolated mitochondria were also exposed to the compound.
- What was measured
- Muscle-fibre composition, mitochondrial respiration, membrane potential, permeability transition, ATP synthesis and cytochrome-c oxidase activity.
- What the paper reported
- Treatment was associated with partial restoration of muscle-fibre composition and mitochondrial measures; some findings came from isolated tissue rather than whole animals.
- Important limitations
- Small groups, induced heart failure and substantial ex vivo work limit translation to ordinary senior dogs. This publication came from the same laboratory and sponsor-supported research line as the cardiac study.
Keep reading
BPC-157
ReadCanine clinical researchBioactive collagen peptides
ReadAnimal / mechanistic researchThymosin Beta-4
ReadDirect canine researchGHK-Cu
ReadAnimal / mechanistic researchKPV
ReadAnimal / mechanistic researchMOTS-c
ReadEmerging researchSelank & Semax
ReadEmerging researchThymosin Alpha-1
Read